Hypothetical Clinical Application of Personalized CRISPR-Mediated Adenine Base Editing for Severe Carbamoyl Phosphate Synthetase 1 Deficiency: A Rigorous Theoretical Framework for Precision Genomic Medicine

Research Summary: A Theoretical Framework for Precision Gene Therapy for CPS1 Deficiency This research presents a detailed theoretical framework for a novel therapeutic application using CRISPR-mediated adenine base editing (ABE) to treat severe carbamoyl phosphate synthetase 1 (CPS1) deficiency. This rare and life-threatening genetic disorder leads to the toxic accumulation of ammonia in the blood, particularly in infants, with current treatments having significant limitations and risks. The paper outlines a hypothetical case study of a 6-month-old infant with a severe disease-causing mutation. The proposed therapeutic model involves using liver-tropic lipid nanoparticles (LNPs) to deliver the gene-editing components intravenously, directly targeting liver cells. The simulated results demonstrate a robust therapeutic response. A key outcome is the achievement of 35% editing efficiency in hepatocytes, a threshold considered sufficient to restore normal metabolic function. This theoretical correction led to the normalization of plasma ammonia levels, increased the patient's dietary protein tolerance, and reduced dependency on chronic medications. The study concludes that this personalized ABE technology holds immense potential as a definitive, precision-based genetic cure for ultra-rare inherited disorders, offering a potentially safer alternative to liver transplantation. However, the paper strongly emphasizes that this is a theoretical model and underscores the critical need for extensive preclinical and clinical investigations to validate the long-term safety and efficacy of this approach before any real-world application.